Efficacy and Resistance of Afatinib in Chinese Non-Small Cell Lung Cancer Patients With HER2 Alterations: A Multicenter Retrospective Study

BACKGROUND: Non-small cell lung cancer (NSCLC) patients with HER2 mutations and amplification may benefit from HER2-targeted therapy, including afatinib. However, the data regarding the clinical activity of afatinib in Chinese patients with NSCLC harboring HER2 alterations are limited. PATIENTS AND...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Zhengbo, Lv, Dongqing, Chen, Shiqing, Huang, Jianhui, Wang, Liping, Xu, Shuguang, Chen, Huafei, Wang, Guoqiang, Lin, Quan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138059/
https://www.ncbi.nlm.nih.gov/pubmed/34026634
http://dx.doi.org/10.3389/fonc.2021.657283

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138059/
https://www.ncbi.nlm.nih.gov/pubmed/34026634
http://dx.doi.org/10.3389/fonc.2021.657283

Ejemplares similares